Summary
Unicycive Therapeutics (UNCY) Loses 21.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Unicycive Therapeutics (UNCY) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Unicycive Therapeutics: A Catalyst Play With Real Fundamental Upside
Unicycive Therapeutics is valued at $8/share, with $2/share in cash and the pipeline—primarily OLC—valued at $6/share. OLC targets hyperphosphatemia by reducing pill burden, aiming for improved patient adherence, with a PDUFA date set for June 29, 2026. Key risks include payer acceptance of premium pricing, patent term uncertainty, and lack of outcomes data supporting improved adherence.
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Unicycive Therapeutics, Inc. (UNCY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Unicycive Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| ABB Alexander Bjornager Bonde Danske Bank A/S | 1 | $5 | $3.61 | -$1.39 | -27.8% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 100 | $477 | $370 | -$107 | -22.43% |
| DS Danny Salinas Cantor Fitzgerald LP | 50,000 | $288,500 | $170,430 | -$118,070 | -40.93% |
| CD Charlie Durham Sterling Capital Management LLC | 135 | $1,039.5 | $499.5 | -$540 | -51.95% |
 Joseph Castro Nuveen LLC | 47,820 | $368,214 | $176,934 | -$191,280 | -51.95% |
Unicycive Therapeutics Inc. (UNCY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Unicycive Therapeutics Inc. ever had a stock split?
Unicycive Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Shalabh K. Gupta CEO | NASDAQ (CM) Exchange | 90466Y202 CUSIP |
| US Country | 21 Employees | - Last Dividend | 20 Jun 2025 Last Split | 12 Jul 2021 IPO Date |
Overview
Unicycive Therapeutics, Inc. is a biotechnology enterprise focused on the innovation of new treatments for kidney diseases within the United States. Established in 2016, the company has positioned itself in the healthcare sector by targeting chronic kidney disease (CKD) and acute kidney injury (AKI), aiming to alleviate the burden of these conditions through groundbreaking therapeutic solutions. Headquartered in Los Altos, California, Unicycive Therapeutics is on a mission to transform the landscape of kidney disease treatment through scientific discovery and clinical application.
Products and Services
- Renazorb
A cutting-edge pharmaceutical candidate, Renazorb is being developed specifically for the management of hyperphosphatemia in patients with chronic kidney disease (CKD). Hyperphosphatemia, characterized by elevated phosphate levels in the blood, is a common and serious condition in individuals with CKD. By addressing this critical aspect of kidney disease management, Renazorb aims to improve the quality of life for those affected by CKD and mitigate the progression of the disease.
- UNI 494
UNI 494 represents Unicycive Therapeutics' innovative approach to treating acute kidney injury (AKI), a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a buildup of waste products in the blood and makes it hard for the kidneys to maintain the proper balance of fluids in the body. UNI 494 is in development to provide a novel treatment option that could significantly improve outcomes for patients suffering from this rapid-onset kidney condition.
Contact Information
